Saar Gill

17.1k total citations · 3 hit papers
174 papers, 6.9k citations indexed

About

Saar Gill is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Saar Gill has authored 174 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 56 papers in Immunology and 53 papers in Molecular Biology. Recurrent topics in Saar Gill's work include CAR-T cell therapy research (106 papers), Acute Myeloid Leukemia Research (29 papers) and Immune Cell Function and Interaction (29 papers). Saar Gill is often cited by papers focused on CAR-T cell therapy research (106 papers), Acute Myeloid Leukemia Research (29 papers) and Immune Cell Function and Interaction (29 papers). Saar Gill collaborates with scholars based in United States, Australia and Germany. Saar Gill's co-authors include Carl H. June, Michael Klichinsky, David L. Porter, Nicholas G. Minutolo, Nicholas R. Anderson, Marco Ruella, Olga Shestova, Saad S. Kenderian, Robert S. Negrin and Katherine D. Cummins and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Saar Gill

169 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

2010 845 citations Saar Gill et al. profile →
Macrophage-Based Approaches for Cancer Immunotherapy

2020 498 citations Saar Gill, Michael Klichinsky et al. profile →
Rapid manufacturing of non-activated potent CAR T cells

2022 184 citations Selene Nuñez-Cruz, Feng Shen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Saar Gill United States	39	4.4k	3.0k	2.0k	1.3k	1.1k	174	6.9k
Claudia Rössig Germany	35	4.4k 1.0×	2.4k 0.8×	1.4k 0.7×	1.4k 1.1×	494 0.4×	157	5.8k
Frederick L. Locke United States	34	5.2k 1.2×	1.4k 0.4×	1.4k 0.7×	1.2k 0.9×	583 0.5×	307	6.0k
Noelle V. Frey United States	34	7.6k 1.7×	2.7k 0.9×	2.2k 1.1×	2.1k 1.7×	1.5k 1.3×	160	9.6k
Shannon L. Maude United States	33	7.7k 1.8×	2.5k 0.8×	2.1k 1.1×	2.2k 1.7×	1.2k 1.1×	107	9.2k
David B. Miklos United States	37	2.2k 0.5×	2.6k 0.8×	1.5k 0.7×	810 0.6×	2.1k 1.9×	224	6.5k
Mikhail Roshal United States	27	2.3k 0.5×	862 0.3×	1.4k 0.7×	593 0.5×	1.2k 1.1×	103	4.3k
Daniel W. Lee United States	26	3.4k 0.8×	937 0.3×	1.0k 0.5×	971 0.8×	382 0.3×	60	4.7k
Julie R. Park United States	46	3.6k 0.8×	972 0.3×	3.3k 1.7×	1.1k 0.8×	305 0.3×	185	8.5k
Chrystal U. Louis United States	20	3.5k 0.8×	1.3k 0.4×	1.1k 0.6×	1.1k 0.8×	244 0.2×	56	4.6k

Countries citing papers authored by Saar Gill

Since Specialization

Citations

This map shows the geographic impact of Saar Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saar Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saar Gill more than expected).

Fields of papers citing papers by Saar Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saar Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saar Gill. The network helps show where Saar Gill may publish in the future.

Co-authorship network of co-authors of Saar Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Saar Gill. A scholar is included among the top collaborators of Saar Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saar Gill. Saar Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Alla Keyzner, Yibin Chen, et al.. (2025). TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation and Cellular Therapy. 31(2). S59–S60.

Shestov, Maksim, Joseph D. Planer, Andrew R. Peterson, et al.. (2025). Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome. JCI Insight. 10(10). 1 indexed citations

Bhagwat, Anand, Maksim Shestov, Olga Shestova, & Saar Gill. (2024). CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature. Blood. 144(Supplement 1). 2040–2040. 1 indexed citations

Bhagwat, Anand, Regina M. Myers, Haley Newman, et al.. (2024). Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123. Blood. 144(Supplement 1). 2946–2946. 1 indexed citations

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2024). A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.. Journal of Clinical Oncology. 42(16_suppl). TPS2678–TPS2678. 1 indexed citations

Wellhausen, Nils, Nils W. Engel, January Salas-McKee, et al.. (2024). Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors. Cancer Immunology Research. 12(9). 1136–1146. 2 indexed citations

Diorio, Caroline, Kimberly Veliz, Olga Shestova, et al.. (2023). CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Advances. 7(16). 4418–4430. 33 indexed citations

Mehta, Rohtesh S., Haris Ali, Voravit Ratanatharathorn, et al.. (2023). A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplantation. 58(9). 991–999. 5 indexed citations

Gill, Saar, et al.. (2023). Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages. Immunological Reviews. 320(1). 236–249. 9 indexed citations

10.

Wellhausen, Nils, Ryan P. O’Connell, Stefanie Lesch, et al.. (2023). Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Science Translational Medicine. 15(714). eadi1145–eadi1145. 75 indexed citations

11.

Matthews, Andrew, Alexander E. Perl, Selina M. Luger, et al.. (2022). Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 6(13). 3997–4005. 53 indexed citations

12.

Loren, Alison W., Elizabeth O. Hexner, Mary Ellen Martin, et al.. (2022). Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and Cellular Therapy. 29(2). 113–118. 2 indexed citations

13.

Heard, Amanda, John M. Warrington, John Lattin, et al.. (2022). Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nature Communications. 13(1). 3367–3367. 40 indexed citations

14.

Saygin, Caner, Gregory W. Roloff, Christopher N Hahn, et al.. (2022). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances. 7(4). 549–554. 23 indexed citations

15.

Ruella, Marco, David M. Barrett, Olga Shestova, et al.. (2019). A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells. Blood. 135(7). 505–509. 24 indexed citations

16.

Ruella, Marco, Michael Klichinsky, Saad S. Kenderian, et al.. (2017). Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery. 7(10). 1154–1167. 153 indexed citations

17.

Cummins, Katherine D., Noelle V. Frey, Anne Marie Nelson, et al.. (2017). Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 130. 1359–1359. 92 indexed citations

18.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations

19.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood. 128(22). 2159–2159. 8 indexed citations

20.

Gill, Saar, Sarah K. Tasian, Marco Ruella, et al.. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood. 123(15). 2343–2354. 363 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact